p53, p63 and p73

p53 Mutant

Reference

• Brachmann RK, Vidal M, Boeke JD. Dominant-negative p53 mutations selected in yeast hit cancer hot spots.Proc Natl Acad Sci U S A. 1996; 93: 4091-4095.
• Inga A, Monti P, Fronza G, Darden T, Resnick MA. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene. 2001; 20: 501-513.
• Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, Mizusawa H, Tanaka N, Koyama H, Namba M, Kanamaru R, Kuroki T. Screening the p53 status of human cell lines using a yeast functional assay. Mol. Carcinog. 19 (4): 243-253, 1997.
• Marutani M, Tonoki H, Tada M, Takahashi M, Kashiwazaki H, Hida Y, Hamada J, Asaka M, Moriuchi T. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res. 1999; 59: 4765-4769.
• Monti P, Campomenosi P, Ciribilli Y, Iannone R, Inga A, Abbondandolo A, Resnick MA, Fronza G. Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene. 2002; 21: 1641-1648.
• Sakuragi N, Watari H, Ebina Y, Yamamoto R, Steiner E, Koelbl H, Yano M, Tada M, Moriuchi T. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int J Cancer. 2005; 116: 514-519.